BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35829744)

  • 21. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.
    Abu Al Karsaneh O; Al Anber A; ALQudah M; Al-Mustafa S; AlMa'aitah H; Sughayer M
    Diagn Pathol; 2023 Jun; 18(1):75. PubMed ID: 37340403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations.
    Yang S; Wang Y; Zhao C; Li X; Liu Q; Mao S; Liu Y; Yu X; Wang W; Tian Q; Pan Y; Xiong A; Chen B; Gao G; Li W; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Transl Lung Cancer Res; 2021 Feb; 10(2):753-765. PubMed ID: 33718019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
    Zhao H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
    Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
    Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
    Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
    J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
    Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.
    Auliac JB; Dô P; Bayle S; Doubre H; Vinas F; Letreut J; Falchero L; Hauss PA; Thomas P; Chouaid C
    Adv Ther; 2019 Aug; 36(8):2161-2166. PubMed ID: 31154630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer.
    Xia Q; Zhu Z; Wang J; Situ D; Zhou N; Jang W
    Tumour Biol; 2012 Oct; 33(5):1719-25. PubMed ID: 22736332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 mutations in Chinese patients with non-small cell lung cancer.
    Song Z; Yu X; Shi Z; Zhao J; Zhang Y
    Oncotarget; 2016 Nov; 7(47):78152-78158. PubMed ID: 27825109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival.
    Haque AK; Syed S; Lele SM; Freeman DH; Adegboyega PA
    Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):103-9. PubMed ID: 12051626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
    Ohashi K; Hotta K; Hirata T; Aoe K; Kozuki T; Ninomiya K; Kayatani H; Yanai H; Toyooka S; Hinotsu S; Takata M; Kiura K
    Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
    Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y
    J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.